一名使用阿那曲唑的乳腺癌患者发生半侧视网膜中央动脉阻塞。
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
作者信息
Karagöz Bulent, Ayata Ali, Bilgi Oğuz, Uzun Gunalp, Unal Melih, Kandemir Emin G, Ozgün Alpaslan, Türken Orhan
机构信息
Department of Medical Oncology, GATA Haydarpaşa Training Hospital, Istanbul, Turkey.
出版信息
Onkologie. 2009 Jul;32(7):421-3. doi: 10.1159/000218369. Epub 2009 Jun 12.
BACKGROUND
Anastrozole, an aromatase inhibitor, is commonly used in the adjuvant treatment of breast cancer. Anastrozole treatment is associated with a risk of thromboembolic events and retinal vascular side effects. Herein, we present a case of hemi-central retinal artery occlusion diagnosed in a breast cancer patient using anastrozole.
CASE REPORT
A 53-year-old woman with a hypertensive and diabetic background was admitted to our hospital with breast cancer. Anastrozole treatment was started after surgery, adjuvant chemotherapy, and radiotherapy. Sudden painless loss of vision in the patient's right eye occurred within 13 months of Anastrozole treatment. A fluorescein angiogram revealed hemi-central retinal artery occlusion.
CONCLUSION
To the best knowledge of the authors, this is the first report of hemi-central retinal artery occlusion in an anastrozole user.
背景
阿那曲唑是一种芳香化酶抑制剂，常用于乳腺癌的辅助治疗。阿那曲唑治疗与血栓栓塞事件风险及视网膜血管副作用相关。在此，我们报告一例使用阿那曲唑的乳腺癌患者被诊断为半侧视网膜中央动脉阻塞的病例。
病例报告
一名有高血压和糖尿病病史的53岁女性因乳腺癌入住我院。术后、辅助化疗及放疗后开始使用阿那曲唑治疗。在阿那曲唑治疗13个月内，患者右眼突然无痛性视力丧失。荧光素血管造影显示半侧视网膜中央动脉阻塞。
结论
据作者所知，这是关于使用阿那曲唑患者发生半侧视网膜中央动脉阻塞的首例报告。
Zotero 插件